Abstract

Myeloid neoplasms (MN) present clinical and molecular heterogeneity and therefore a risk-adapted treatment strategy is mandatory. In MN, classification and prognostic tools based on clinical and morphologic criteria are being complemented by introducing genomic features. The clinical implementation of next-generation classifications and prognostic systems requires the availability of a robust methodological framework together with a solution to provide access to these technologies for clinicians.